0370 1500 100

Vioxx claims

Vioxx claim


Vioxx, generically known as Rofecoxib, was withdrawn from worldwide use on 30 September 2004 following new clinical trial results which showed an increased risk of serious thrombotic events including heart attacks and strokes. Until its withdrawal, Vioxx was used by approximately 400,000 people in the UK. It belongs to a class of drugs known as Cox-11 Inhibitors which are prescribed for symptoms of rheumatoid arthritis and osteo-arthritis.

The results of a 3 year study for colon cancer indicate that the drug raises the risk of heart attack and stroke. The risk appears to increase after 18 months of treatment for patients taking Vioxx. Similar results emerged from a recent study by the US Food & Drug Administration (FDA). There is evidence that Merck knew for some time prior to September 2004 that Vioxx was associated with adverse health effects.

Vioxx claims are likely to proceed against Merck Inc. in the US Courts. The claims for some non-US based claimants, including some UK claimants, have already been commenced in New Jersey (which is where Merck Inc is based and where the claims of other non-US claimants would have to be brought). It will be necessary for UK claimants in the first instance to seek to persuade the US Courts to hear their claims.

Making a Vioxx claim

It may be possible for you to pursue a claim if you have suffered side effects as a consequence of taking Vioxx medication. Alternatively, if you have lost a relative who was taking Vioxx at the time of their death and you suspect that Vioxx may have caused or contributed to their death then it may also be possible to pursue a claim. In these circumstances, a dependent of the deceased may pursue a claim for compensation.

If you would like to speak to a member of the team regarding a Vioxx claim or obtain further information, you can fill in our online claims form for free advice.

Alternatively, if your claim affects a number of people, please visit our group action section to see how we could help you.